276 related articles for article (PubMed ID: 23545904)
1. Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusion.
Gumuskaya B; Gurel B; Fedor H; Tan HL; Weier CA; Hicks JL; Haffner MC; Lotan TL; De Marzo AM
Prostate Cancer Prostatic Dis; 2013 Jun; 16(2):209-15. PubMed ID: 23545904
[TBL] [Abstract][Full Text] [Related]
2. Heterogeneity and chronology of PTEN deletion and ERG fusion in prostate cancer.
Krohn A; Freudenthaler F; Harasimowicz S; Kluth M; Fuchs S; Burkhardt L; Stahl P; C Tsourlakis M; Bauer M; Tennstedt P; Graefen M; Steurer S; Sirma H; Sauter G; Schlomm T; Simon R; Minner S
Mod Pathol; 2014 Dec; 27(12):1612-20. PubMed ID: 24762546
[TBL] [Abstract][Full Text] [Related]
3. The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion.
Burdelski C; Menan D; Tsourlakis MC; Kluth M; Hube-Magg C; Melling N; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Simon R; Schlomm T; Steurer S; Krech T
BMC Cancer; 2015 Jul; 15():538. PubMed ID: 26202067
[TBL] [Abstract][Full Text] [Related]
4. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer.
Krohn A; Diedler T; Burkhardt L; Mayer PS; De Silva C; Meyer-Kornblum M; Kötschau D; Tennstedt P; Huang J; Gerhäuser C; Mader M; Kurtz S; Sirma H; Saad F; Steuber T; Graefen M; Plass C; Sauter G; Simon R; Minner S; Schlomm T
Am J Pathol; 2012 Aug; 181(2):401-12. PubMed ID: 22705054
[TBL] [Abstract][Full Text] [Related]
5. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
[TBL] [Abstract][Full Text] [Related]
6. The prognostic impact of high Nijmegen breakage syndrome (NBS1) gene expression in ERG-negative prostate cancers lacking PTEN deletion is driven by KPNA2 expression.
Grupp K; Boumesli R; Tsourlakis MC; Koop C; Wilczak W; Adam M; Sauter G; Simon R; Izbicki JR; Graefen M; Huland H; Steurer S; Schlomm T; Minner S; Quaas A
Int J Cancer; 2014 Sep; 135(6):1399-407. PubMed ID: 24510842
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneity and chronology of 6q15 deletion and ERG-fusion in prostate cancer.
Kluth M; Meyer D; Krohn A; Freudenthaler F; Bauer M; Salomon G; Heinzer H; Michl U; Steurer S; Simon R; Sauter G; Schlomm T; Minner S
Oncotarget; 2016 Jan; 7(4):3897-904. PubMed ID: 26684029
[TBL] [Abstract][Full Text] [Related]
8. Concurrent TMPRSS2-ERG and SLC45A3-ERG rearrangements plus PTEN loss are not found in low grade prostate cancer and define an aggressive tumor subset.
Hernández S; Font-Tello A; Juanpere N; de Muga S; Lorenzo M; Salido M; Fumadó L; Serrano L; Cecchini L; Serrano S; Lloreta J
Prostate; 2016 Jun; 76(9):854-65. PubMed ID: 26959281
[TBL] [Abstract][Full Text] [Related]
9. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression.
Han B; Mehra R; Lonigro RJ; Wang L; Suleman K; Menon A; Palanisamy N; Tomlins SA; Chinnaiyan AM; Shah RB
Mod Pathol; 2009 Aug; 22(8):1083-93. PubMed ID: 19407851
[TBL] [Abstract][Full Text] [Related]
10. Novel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma.
Bhalla R; Kunju LP; Tomlins SA; Christopherson K; Cortez C; Carskadon S; Siddiqui J; Park K; Mosquera JM; Pestano GA; Rubin MA; Chinnaiyan AM; Palanisamy N
Mod Pathol; 2013 Jun; 26(6):835-48. PubMed ID: 23348902
[TBL] [Abstract][Full Text] [Related]
11. TMPRSS2-ERG gene fusion is rare compared to PTEN deletions in stage T1a prostate cancer.
Fisher KW; Zhang S; Wang M; Montironi R; Wang L; Baldrige LA; Wang JY; MacLennan GT; Williamson SR; Lopez-Beltran A; Cheng L
Mol Carcinog; 2017 Mar; 56(3):814-820. PubMed ID: 27500376
[TBL] [Abstract][Full Text] [Related]
12. A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer.
Ahearn TU; Pettersson A; Ebot EM; Gerke T; Graff RE; Morais CL; Hicks JL; Wilson KM; Rider JR; Sesso HD; Fiorentino M; Flavin R; Finn S; Giovannucci EL; Loda M; Stampfer MJ; De Marzo AM; Mucci LA; Lotan TL
J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26615022
[TBL] [Abstract][Full Text] [Related]
13. PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade.
Yoshimoto M; Ding K; Sweet JM; Ludkovski O; Trottier G; Song KS; Joshua AM; Fleshner NE; Squire JA; Evans AJ
Mod Pathol; 2013 Mar; 26(3):435-47. PubMed ID: 23018874
[TBL] [Abstract][Full Text] [Related]
14. Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer.
Leinonen KA; Saramäki OR; Furusato B; Kimura T; Takahashi H; Egawa S; Suzuki H; Keiger K; Ho Hahm S; Isaacs WB; Tolonen TT; Stenman UH; Tammela TL; Nykter M; Bova GS; Visakorpi T
Cancer Epidemiol Biomarkers Prev; 2013 Dec; 22(12):2333-44. PubMed ID: 24083995
[TBL] [Abstract][Full Text] [Related]
15. Molecular evidence that invasive adenocarcinoma can mimic prostatic intraepithelial neoplasia (PIN) and intraductal carcinoma through retrograde glandular colonization.
Haffner MC; Weier C; Xu MM; Vaghasia A; Gürel B; Gümüşkaya B; Esopi DM; Fedor H; Tan HL; Kulac I; Hicks J; Isaacs WB; Lotan TL; Nelson WG; Yegnasubramanian S; De Marzo AM
J Pathol; 2016 Jan; 238(1):31-41. PubMed ID: 26331372
[TBL] [Abstract][Full Text] [Related]
16. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate.
Carver BS; Tran J; Gopalan A; Chen Z; Shaikh S; Carracedo A; Alimonti A; Nardella C; Varmeh S; Scardino PT; Cordon-Cardo C; Gerald W; Pandolfi PP
Nat Genet; 2009 May; 41(5):619-24. PubMed ID: 19396168
[TBL] [Abstract][Full Text] [Related]
17. Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies.
Tomlins SA; Palanisamy N; Siddiqui J; Chinnaiyan AM; Kunju LP
Arch Pathol Lab Med; 2012 Aug; 136(8):935-46. PubMed ID: 22849743
[TBL] [Abstract][Full Text] [Related]
18. Aquaporin 5 expression is frequent in prostate cancer and shows a dichotomous correlation with tumor phenotype and PSA recurrence.
Pust A; Kylies D; Hube-Magg C; Kluth M; Minner S; Koop C; Grob T; Graefen M; Salomon G; Tsourlakis MC; Izbicki J; Wittmer C; Huland H; Simon R; Wilczak W; Sauter G; Steurer S; Krech T; Schlomm T; Melling N
Hum Pathol; 2016 Feb; 48():102-10. PubMed ID: 26614400
[TBL] [Abstract][Full Text] [Related]
19. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome.
Yoshimoto M; Joshua AM; Cunha IW; Coudry RA; Fonseca FP; Ludkovski O; Zielenska M; Soares FA; Squire JA
Mod Pathol; 2008 Dec; 21(12):1451-60. PubMed ID: 18500259
[TBL] [Abstract][Full Text] [Related]
20. PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer.
Bismar TA; Yoshimoto M; Vollmer RT; Duan Q; Firszt M; Corcos J; Squire JA
BJU Int; 2011 Feb; 107(3):477-85. PubMed ID: 20590547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]